Wednesday, January 15, 2025
1/15/2025
ABSTRACT — Combination chemoradiation is utilized to treat multiple gastrointestinal (GI) cancers including rectal cancer. Rectal cancer affects 40,000 people per year in the US. Approximately 85% of patients have an incomplete or poor response to treatment increasing their risk of recurrence. We have found that poor responders harbor sub-clones that are more resistant to treatment, and that the enzyme ST6Gal-1 is enriched in these sub- clones. ST6Gal-1 is a Golgi glycosyltransferase that adds the negatively-charged sugar, sialic acid (SA), to specific proteins destined for the cell surface. SA can have profound effects on the structure and function of proteins. ST6Gal-1 is one of the most pervasively upregulated glycosyltransferases in cancer cells. ST6Gal-1 has been shown to specifically promote tumor cell survival and resistance via sialylation. In addition, ST6Gal-1 has been found in extracellular vesicles (ECVs) made by cancer cells. ECVs are particles with a lipid membrane that contains RNA and protein cargo; thus, they are potential mediators of transferable resistance between cancer sub-clones. The role of ST6Gal-1 and ECVs in resistance to chemoradiation has not been investigated. The overall objective of this application is to ascertain the role of ST6Gal-1 in innate and transferable resistance to chemoradiotherapy in rectal cancer. Based on our preliminary data, we hypothesize that ST6Gal-1 mediates resistance to chemoradiation in individual sub-clones in rectal cancer, that this resistance is transferred to other sub-clones via ECVs spreading resistance, and that this resistance is regulated by ST6Gal-1 cleavage by BACE1. We have found that ST6Gal-1 is increased in rectal cancer models after treatment with chemoradiation. We will investigate our hypothesis with 3 aims: AIM 1 — Determine the role of ST6Gal-1 in chemoradiation resistance in human rectal cancer. We hypothesize that ST6Gal-1 causes treatment resistance after chemoradiation by inhibiting apoptosis. We will employ cell sorting, sequencing, and shRNA approaches. We will also conduct studies to investigate its function in patient samples. AIM 2 — Determine if ECVs carrying ST6Gal-1 transfer resistance to chemoradiation between sub-clones in rectal cancer. We hypothesize that ECVs act as vectors that impart resistance to chemoradiotherapy from sub-clone to sub-clone by trafficking ST6Gal-1, and thus, glycoprotein sialylation, in rectal cancer causing decreased apoptosis in the recipient sub-clones. AIM 3 — Determine if BACE1 promotes chemoradiosensitivity in rectal cancer due, in part, to ST6Gal-1 cleavage. We show that BACE1 mRNA is increased in tumors from patients who completely respond to chemoradiotherapy. BACE1 is known to cleave ST6Gal-1, and we found through inhibitor studies that BACE1 appear to regulate SA due to cleavage of ST6Gal-1 by BACE1. This research will evaluate a previously unknown mechanism of resistance to chemoradiotherapy in rectal cancer, with future potential for development of novel therapeutics that could target multiple resistant sub-clones across multiple GI adenocarcinomas, where the standard of care is pre-operative chemoradiation treatment.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).